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Personal genomics and whole-genome sequencing are rapidly becoming established on the 
spectrum of genomic research and service provision. It appears that we do in fact possess curiosity 
about our genomes, enough to prompt many to purchase DTC testing and more to consider it. 
McGuire and colleagues' study (2009) and Lee and Crawley's reflection (2009) provide a useful 
snapshot of emerging issues in personal genomics. Yet the momentum of these technologies 
suggests we need to act quickly in deliberating their implications. 
This commentary will draw out and provide some initial reflection on some of the key ethical issues 
arising in DTC genomics. This will incorporate an analysis of an online personal genomics broadcast 
that has recently taken place in the United Kingdom: the Routes Game. Additionally, a claim is 
advanced that further empirical reflection on DTC genomics should rest on a strong theoretical 
ethical foundation. 
DTC genomics is not yet as visible in the United Kingdom as it is in North America. Nevertheless 
debates over DTC genomics are ongoing and the Human Genetics Commission has made 
recommendations about so-called ‘over the counter’ testing that focus on the problem of mis-selling 
(Human Genetics Commission 2007). A prominent science journalist has had his genome sequenced 
and pointed out the pitfalls of DTC interpretation (Henderson 2008a; 2008b). In 2009, DTC genomics 
and its interpretation have gained an increased online presence courtesy of the “Routes game” 
(Channel 4 2009). 
Routes, which ran for 8 weeks in early 2009, was an online educational package designed to take the 
concept of personal genomics to an adolescent audience and in the process to teach them about 
genetics, evolution and the human genome. It was developed collaboratively by the education 
department of a public broadcaster and a scientific research charity. The site focuses on 
developments in genomics, including personal genomics, and encourages its audience to start 
thinking about the impact it will have. The site is interactive and is linked to social networking sites 
Facebook and MySpace, social bookmarking service Delicious and social news site Digg. 
The Routes DTC genomics story was personified by Katherine Ryan, a Canadian comedian living in 
London. Katherine, aged 23, is a survivor of melanoma, is pregnant and has the autoimmune disease 
lupus. She volunteered to take herself on a very public journey through her own genetic makeup by 
obtaining a DTC test from a commercial company, after receiving counselling from an independent 
genetic counsellor. This was summarized each week by a themed video to document the testing 
process and the results she obtained (YouTube 2009). 
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DTC genomics both raises new issues and offers new nuances to previous debates. It challenges 
current models of clinical service provision and could re-shape professional-patient relationships, 
not least what constitutes a ‘professional’ health care provider. No matter how often companies 
providing DTC testing claim that this is not health information, it is certainly being interpreted as 
such (McGuire et al. 2009). This gives rise to a prima facie responsibility on DTC providers to ensure 
that this information is correctly framed and contextualized, perhaps via ongoing clinical support. 
This is not yet happening—Katherine's results, and those of the United Kingdom science journalist, 
were provided by e-mail without further clinical input. Both then sought further expert help to 
interpret them. Katherine commented: 
You'd have to get, like, Greg [a scientist friend of hers] or someone to look at it, because it's 
like … weird numbers that don't mean anything … Oh, I have a really elevated risk of prostate 
cancer. Wow! This is pretty accurate, this test. No, but maybe it might mean other things. 
See, that's the thing with this. It just means, like … not a lot to us (YouTube, 2009, Week 2: 
Sick). 
The lack of clinical integration in DTC genomics is under-explored and warrants further 
consideration. No matter how a service is marketed, if consumers are interpreting this information 
as health-related it will impact on clinical services (McGuire et al. 2009). Even though clinicians are 
effectively bypassed by most DTC genomics services, they will no doubt be approached afterwards 
for interpretation and follow-up, potentially creating a drain on resources and problems of specialist 
education. 
Linked to the issue of ongoing clinical support is the presumption of DTC genomics providers that 
recipients of results will be active consumers of the information that is provided. However not all 
consumers are going to appreciate the difference between absolute and relative risk, assuming 
these are even accurate. DTC testing for serious later-onset diseases should be offered with at least 
a degree of counselling, as professional experience constantly shows that this protects people's well-
being in the longer term. DTC companies may well reject this as paternalistic but a counter-
argument is that this either does not constitute paternalism or that if it does, it is justifiable. 
Personal genomics is also spearheading a shift in the management of patient information, as 
patients will become the new guardians of their data. This will no doubt be framed by the companies 
who market these tests as empowering for individuals and their future choices. But with this choice 
will come the task (and perhaps, in the longer term, the responsibility) to manage this information 
and interpret it in light of further developments in the field. Who will update this information over 
time? The potential burden arising from this task should not be underestimated. 
The concept and rhetoric of ‘empowerment’ promoted by DTC genomics companies, highlighted by 
McGuire and colleagues (2009) and Lee and Crawley (2009), also requires further exploration and 
debate. Was Katherine ‘empowered’ by this information, or merely bemused? What does 
empowerment mean from a moral perspective? Is this a ‘good’ thing for DTC genomics? How does 
this empowerment sit with existing models of professionals and consumers (not always patients, as 
the majority accessing DTC genomics will be well)? What might the practical applications be? 
Empowerment may not be intrinsically good, as reframing recipients of this information as 
advocates may come at a cost to other domains of their medical care. This possible trade-off 
requires conceptual and practical exploration. As Lee and Crawley (2009) state, we should be wary 
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of recasting this information as ‘fun’ given that its pleiotropic nature could quickly change its 
meaning in the future. 
Creating new social networks based on DNA also grates against more traditional presumptions of 
privacy and familial communication of genetic information. While sharing of appropriate data with 
other potentially at-risk individuals should occur, careful consideration should be given to the impact 
of this information on relatives. Ill-considered or poorly framed information sharing can cause 
psychological harm. A decision to share information about a risk for a particular genetic condition is 
therefore usually a considered decision made in collaboration with a clinical team. Information from 
DTC testing will, in contrast, be much greater in volume and of uncertain significance. While a great 
deal of this information will be inert for relatives, some genetic risks will emerge particularly as more 
gene-disease relationships and environmental interactions become known. DTC recipients should 
give careful consideration to whom and how they share this information as it may not be universally 
welcomed by all. 
Despite these concerns, it is also worth bearing in mind that professionals and academics, who have 
been absorbed in analysing issues in Mendelian genetics for so long, could be over-interpreting the 
ethical concerns arising from DTC genomic information. Consumers may not be the vulnerable group 
that we often worry they are. They may be perfectly capable of taking DTC genomic information and 
its limitations into due consideration when conceiving their overall health. As Katherine stated: 
Like, what can they tell me in the genetic testing that's going to be worse than the day 
someone said, “You have cancer”? Not “You could have cancer.” Not “You have the genome 
for cancer (YouTube, 2009, week 2: Sick). 
In a later video, she also comments in response to an incorrect prediction about her food 
preferences: 
I really like the fact that the genetics didn't predict what you like. … I mean, for me that's very 
reassuring that we can't learn everything from science (YouTube, 2009, Week 6: Tasty). 
DTC information could therefore increase people's overall health awareness, even if it does seem to 
be an expensive way to be told to eat more greens and do more exercise. Lee and Crawley (2009) 
also correctly point out that this information could lead to the creation of new ties between 
individuals, groups and organizations. Social networks may therefore be used to create new kinds of 
communities or to re-connect individuals. These benefits should be carefully monitored. 
In reading both DTC articles in this issue, as O'Connor (2009) recognizes it is slightly frustrating that 
they both undertake to map the ethical landscape, but neither of them use this to advance a 
position as to how personal genomics should proceed. There is therefore a pressing need for further 
theoretical reflection on the ethical issues arising from DTC genomics to create a robust foundation 
for ethical discourse and further empirical investigation. The manner in which empirical results 
should influence theoretical debate also requires deliberation, as other commentaries have 
highlighted. Empirical follow-up for individuals who have already had testing is also required. 
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